Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe “for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care.” 

Read Media Release